SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity.
Am J Clin Pathol
; 154(4): 459-465, 2020 09 08.
Article
em En
| MEDLINE
| ID: mdl-32666092
ABSTRACT
OBJECTIVES:
Initial reports indicate adequate performance of some serology-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course.METHODS:
A total of 967 subjects were tested for IgG antibodies reactive to SARS-CoV-2, including 172 suspected cases of SARS-CoV-2, 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for polymerase chain reaction (PCR)-based respiratory viral panel. A subgroup of SARS-CoV-2 PCR-positive cases was tested for IgM antibodies by proteome array method.RESULTS:
All specificity and cross-reactivity specimens were negative for SARS-CoV-2 IgG antibodies (0/795, 0%). Positive agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from symptom onset, with less than 100% sensitivity attributable to a case with severe immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course with respect to IgG and IgM levels.CONCLUSIONS:
The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse cross-reactivity. Measures of IgG and IgM antibodies did not predict disease severity in our patient population.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Índice de Gravidade de Doença
/
Imunoglobulina G
/
Infecções por Coronavirus
/
Técnicas de Laboratório Clínico
/
Betacoronavirus
/
Anticorpos Antivirais
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article